Evolus (EOLS) Stock Price, News & Analysis

Company Overview

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key Stats

• Today's Range: $9.11 to $9.28
• 50-Day Range: $9.10 to $12.08
• 52-Week Range: $8.67 to $17.82
• Volume: 424,231 shs
• Average Volume: 754,518 shs
• Market Capitalization: $597.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.75
• Consensus Rating: Buy

Evolus Stock Analysis - MarketRank™

Evolus scored higher than 72% of companies evaluated by MarketBeat, and ranked 853rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evolus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evolus is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evolus is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evolus has a P/B Ratio of 103.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.49% of the float of Evolus has been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Evolus has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evolus does not currently pay a dividend.

Dividend Growth

Evolus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.27

Percentage of Shares Shorted

17.49% of the float of Evolus has been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Evolus has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Evolus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Evolus insiders have sold 713.28% more of their company's stock than they have bought. Specifically, they have bought $189,000.00 in company stock and sold $1,537,090.00 in company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Evolus is held by insiders.

Percentage Held by Institutions

90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EOLS Stock Analysis - Frequently Asked Questions

How have EOLS shares performed this year?

Evolus' stock was trading at $11.04 on January 1st, 2025. Since then, EOLS shares have decreased by 16.0% and is now trading at $9.27.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The company earned $20.58 million during the quarter, compared to analysts' expectations of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 759.04% and a negative net margin of 20.40%.
Read the conference call transcript.

When did Evolus IPO?

Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 3/23/2021
• Today: 7/03/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EOLS
• CIK: 1570562
• Web: www.evolus.com
• Phone: (949) 284-4555
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.75
• High Stock Price Target: $27.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +156.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.42 million
• Net Margins: -20.40%
• Pretax Margin: -20.15%
• Return on Equity: -759.04%
• Return on Assets: -20.14%

Debt

• Debt-to-Equity Ratio: 22.00
• Current Ratio: 2.34
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: $266.27 million
• Price / Sales: 2.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.09 per share
• Price / Book: 103.00

Miscellaneous

• Outstanding Shares: 64,480,000
• Free Float: 60,672,000
• Market Cap: $597.73 million
• Optionable: Optionable
• Beta: 0.97